Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.56 |
| ▸ | CDK1 | P06493 | 3/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642440 | 0.87 | KIT (0.50) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL25145758 | 0.81 | ADORA2A (0.54) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL20928367 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL3604759 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL16041244 | 0.80 | CDC7 (0.59) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL31240593 | 0.80 | CDC7 (0.59) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL29955037 | 0.80 | ADORA2A (0.52) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL31238245 | 0.78 | ADORA2A (0.58) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL29957029 | 0.76 | ADORA2A (0.56) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL26102930 | 0.76 | CDC7 (0.62) | ADORA2AADORA1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | claimed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| CN-1665809-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| CN-1615873-A | Azaindoles compound | AVENTIS PHARMA LTD (GB) | 2005-05-18 | — | — | CN | claimed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | claimed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | claimed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | claimed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | claimed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | claimed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | claimed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| CN-100509811-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | ADORA2A 1586/4885ADORA1 2801/4885CCNB2 194/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | ADORA2A 680/4885ADORA1 773/4885CCNB2 381/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | ADORA2A 1584/4885ADORA1 3024/4885CCNB2 244/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | ADORA2A 940/4885ADORA1 1034/4885CCNB2 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.